NEW YORK (GenomeWeb News) - Caprion Pharmaceuticals has withdrawn its initial public offering due to “adverse market conditions,” the company said today.
Drug makers use the company’s CellCarta product, a proteomics technology, to profile proteins in solid tissues and plasma for disease-target identification and predictive medicine.
The technology relies on sample prep and purification, mass spectrometry analysis, quantitative expression of protein peptides, and bioinformatics-based protein identification.
Additional details were not provided.